Sana Biotechnology, Inc. (SANA) News
Track canonical SquawkNews coverage tagged to SANA, Sana Biotechnology, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 11 indexed stories across 6 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
SANA: IND and phase I/II trial for diabetes therapy and first-in-human CAR T data expected within 12 months
Two innovative platforms are advancing: a hypoimmune cell therapy for type 1 diabetes, with an IND and phase I/II trial planned by year-end, and an in vivo CAR T platform targeting cancer, with first-in-human data for SG
NEWS | Sep 15, 2026, 04:33 PM UTC
L
SANA: Clinical milestones for diabetes and CAR T therapies are on track, with key trials imminent
Significant progress was highlighted for both the type 1 diabetes and in vivo CAR T platforms, with key clinical milestones expected in the next 12 months. Strategic collaboration with Mayo Clinic is accelerating trial r
NEWS | Sep 15, 2026, 04:07 PM UTC
L
SANA: Gene-edited islet therapy for type 1 diabetes nears clinical trial, with CAR T data expected in 2027
The discussion highlighted progress toward a gene-edited, stem cell-derived islet therapy for type 1 diabetes, with IND clearance and a phase I trial expected this year. The in vivo CAR T platform is advancing, with clin
NEWS | Sep 14, 2026, 10:58 PM UTC
L
SANA: Gene-modified islet cell therapy for type 1 diabetes nears phase I trial, with strong clinical and financial momentum
The company is advancing gene-modified islet cell therapy for type 1 diabetes, aiming to start a phase I trial by year-end, and is developing an in vivo CAR T platform for blood cancers. Manufacturing scalability, regula
NEWS | Sep 14, 2026, 09:52 PM UTC
L
Sana signals progress on gene-modified islet and in vivo CAR T programs
TradingView News says Sana is progressing toward a one-time gene-modified islet therapy for type 1 diabetes, with IND filing and phase I/II trials expected soon. In vivo CAR T programs are also advancing, focused on safe
EQUITY | Sep 08, 2026, 03:13 PM UTC
M
Sana programs near clinical milestones; SC451 IND and dosing expected
Sana said SC451 is targeting type 1 diabetes and an in vivo CAR T platform is focused on oncology. An IND filing and initial patient dosing for SC451 are expected this year, with pivotal data anticipated next year.
EQUITY | Sep 08, 2026, 02:33 PM UTC
M
SANA platforms advance toward clinical trials for diabetes and cancer
Hypoimmune islet cell technology is advancing as a potential functional cure for type 1 diabetes, citing long-term cell survival and immune evasion without immunosuppression. Its in vivo fusosome CAR T platform is moving
EQUITY | Sep 08, 2026, 12:47 PM UTC
L
Sana Biotechnology updates corporate presentation on SC451 and CAR T programs
Sana Biotechnology said its updated corporate presentation outlines progress toward filing an IND for SC451 this year and advances in its in vivo CAR T fusosome programs.
REGULATION | Sep 08, 2026, 12:03 PM UTC
L
Sana Biotechnology to Present at September 2026 Investor Conferences
Sana Biotechnology announced it will present at September 2026 investor conferences.
EQUITY | Sep 01, 2026, 08:05 PM UTC
H
Sana Biotechnology Insiders Face Fiduciary Probe
Sana Biotechnology insiders probed for fiduciary breaches
EQUITY | Jul 29, 2026, 02:09 PM UTC
L
Sana Biotechnology To Present Data From Allogeneic Primary Islet Cell Therapy At European Association For The Study Of Diabetes
Sana Biotechnology, Inc. (NASDAQ: SANA ), a company focused on changing the possible for patients through engineered cells, today announced a symposium presentation highlighting clinical data from an investigator-sponsor
EQUITY | Jul 01, 2026, 01:05 PM UTC